.... from their first and only announcement !!! And it is a...

.... from their first and only announcement !!!

And it is a positive thing that ATH will focus on ATH434, not a negative thing. Brain degeneration experts do not become microbiologists in a moment. ATH needs both. Its neurodegeneration team is very small; in fact, they are being supported by outsiders even in neurodegeneration issues such as Stefanova, etc.
With PBT2 ATH has to rely totally on outsiders and for this, they have the PBT2 inventors and Queensland University microbiologists, who will share the royalties with ATH. The money needed will come from outside. But to get this outside money, you need a good plan, even for the antibiotic-resistance fund. If there is a new molecule to support the goal of the antibiotic-resistance fund, it must be PBT2, IMO.

Stamler told last week that there are some "academics" telling their interest in PBT2. We know the otitis media project by Dr. Neville. I think there will be an announcement in a few months.